Omniab
OmniAb Inc is an American multinational biotechnology platform enterprise specializing in the discovery, research, and provision of proprietary transgenic animal platforms, artificial intelligence-enabled antibody discovery technologies, and genetic engineering platforms utilized by global pharmaceutical and biotechnology enterprises to discover and develop novel therapeutic antibodies. Operating advanced biological discovery facilities in Emeryville, California, the company empowers partners to accelerate antibody drug development. Its core business operations encompass transgenic platform licensing, AI-driven antibody discovery, genetic engineering research, and biopharmaceutical partnership administration. Revenue is derived primarily from technology platform access fees, research milestone payments, and future commercial royalty streams from partnered antibody drugs. OmniAb holds a leading market position in transgenic antibody discovery platforms and biopharmaceutical technology licensing. The company is headquartered in Emeryville, California, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker OABI.
2 of the funds FundTelligence covers report a position in Omniab.
- Legal name
- OMNIAB INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Omniab
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)